![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 12")
Some Cannabinoids May Ease Common Chronic Pain Conditions, Study Finds
✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainResearchCBDTHCCannabinoidsSafetyHemp Why This Matters Clinicians need current evidence on cannabinoid efficacy…
A Synthetic Cannabinoid Did NOT Reduce Opioid Use After Knee Replacement Surgery
A new postoperative randomized trial found no significant opioid reduction from a synthetic cannabinoid after total knee arthroplasty. The findings challenge broad assumptions that cannabinoids reliably reduce opioid use in every pain setting. The study…
Evidence-Based Cannabis for Dementia-Related Behavioral Agitation
A meta-analysis of 10 RCTs shows medical cannabis can reduce dementia-related agitation—a behavioral symptom that devastates both patients and caregivers. Cannabinoids showed effectiveness comparable to antipsychotics but with a safer profile, especially…
Cannabinoids for Autism
This Evidence Watch reviews a 2026 systematic review on cannabinoids for autism in children and adolescents. The paper found limited RCT evidence, with one whole-plant high-CBD, low-THC extract showing improvement in global clinical impression and social…
Cannabis Prescriptions Did Not Lower Opioid Use in GI Cancer Patients Starting Chemotherapy
Among 144,981 adults with a GI cancer, only 2.4% received an FDA-approved cannabinoid prescription within 90 days of chemotherapy initiation. Cannabinoid recipients were more likely to receive opioids than nonrecipients (60.6% vs. 31.1%, p
Cannabis Prescriptions Did Not Lower Opioid Use in GI Cancer Patients Starting Chemo, Large EHR Study Finds
Among 144,981 patients, 2.4% received cannabinoids within 90 days of chemotherapy initiation. Cannabinoid recipients were more likely to receive opioids than nonrecipients (60.6% vs. 31.1%, p
Cannabis & Dental Care
Clinical Relevance #62 Emerging but Limited Evidence Mechanistic promise exists, but clinical translation remains early and uncertain. Clinical Insight Cannabis in dentistry is biologically plausible but clinically immature. The key risk is…
What a 2026 Lancet Psychiatry Review Actually Shows, and What It Doesn’t
This cannabinoids mental health meta-analysis reviews 54 randomized trials across psychiatric and substance use conditions. It identifies modest benefits in insomnia, Tourette syndrome, ASD traits, and cannabis withdrawal, but with low certainty. For…
Head Down Tilt 15° to Increase Collateral Flow in Acute Ischemic Stroke: Rationale and Study Protocol of a Multicenter, Randomized, Proof-of-Concept, Phase 2a/b Trial in Patients Treated With Mechanical Thrombectomy (DOWN-SUITE).
Collateral blood flow is a critical determinant of successful recanalization in acute ischemic stroke caused by large vessel occlusion. Head down tilt -15° (...
Endocannabinoid System Research: Cannabis Mental Health Care
Clinical Takeaway Cannabinoids show limited evidence for treating mental disorders and substance use disorders in controlled trials, with safety concerns that require further investigation. Current research does not support cannabinoids as a primary…